NCT06128044View on ClinicalTrials.gov

CRISPR-Edited Allogeneic Anti-CLL-1 CAR-T Cell Therapy in Patients With Relapsed/Refractory Acute Myeloid Leukemia

PHASE1TerminatedINTERVENTIONAL
Enrollment

12

Participants

Timeline

Start Date

February 8, 2024

Primary Completion Date

May 30, 2025

Study Completion Date

May 30, 2025

Conditions
Acute Myeloid Leukemia, in RelapseAcute Myeloid Leukemia Refractory
Interventions
DRUG

CB-012

CB-012 allogeneic CAR-T cell therapy targeting CLL-1 Cyclophosphamide and Fludarabine chemotherapy for lymphodepletion

Trial Locations (10)

10022

Weill Cornell Medical College, New York

10065

Memorial Sloan Kettering Cancer Center (MSKCC), New York

30342

The Blood & Marrow Transplant Group of Georgia (BMTGA), Atlanta

33612

Moffitt Cancer Center, Tampa

37203

TriStar Bone Marrow Transplant, LLC, Nashville

53226

Medical College of Wisconsin, Milwaukee

77030

MD Anderson Cancer Center, Houston

80218

Colorado Blood Cancer Institute, Denver

35249-0001

The University of Alabama at Birmingham (UAB), Birmingham

98109-1023

Fred Hutchinson Cancer Center, Seattle

Sponsors
All Listed Sponsors
lead

Caribou Biosciences, Inc.

INDUSTRY